ReviewSaudi medical journal2026
Women's cardiovascular health in 2025:
Review in Saudi medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is the leading cause of death among women globally. Recognition of sex-specific risk factors, pathophysiology, and clinical presentations has established women's cardiovascular health as a research and clinical priority. Pregnancy complications, premature menopause, and autoimmune disease, are now identified as long-term contributors to cardiovascular risk, while female-predominant syndromes such as ischemia with non-obstructive coronary arteries and heart failure with preserved ejection fraction are increasingly acknowledged. Novel therapies and updated guidelines emphasize psychosocial determinants, reproductive history, and postpartum risk assessment in prevention and management. Despite these advances, women remain underdiagnosed, undertreated, and underrepresented in clinical trials. Diagnostic delays and limited access to therapies and rehabilitation persist globally, with disparities pronounced in Saudi Arabia, where obesity, diabetes, and hypertension are highly prevalent. Closing these gaps requires sustained investment in sex-specific research, equitable access to evidence-based care, and integration of women's cardiovascular health into national strategies under Saudi Vision 2030.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.